Rocket Pharmaceuticals Inc
RCKT
Get informed when a big investor buys or sells
+ FollowMarket Cap$335.22M
Close$
$0.47
83.8% downside
Current Fair Value
83.8% downsideOvervalued by 83.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $335.22 Million |
|---|---|
| Enterprise Value | $310.38 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.01 |
| Beta | 0.52 |
| Outstanding Shares | 112,134,059 |
Return
| Return on Equity | -87.96% |
|---|---|
| Return on Assets | -73.36% |
| Return on Invested Capital | -79.88% |
Valuation & Multiples
| P/E Ratio | -1.64 |
|---|---|
| PEG | 7.34 |
| Price to Sales | - |
| Price to Book Ratio | 1.46 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.49 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.41
Average shareholder expectationRevenue Estimate
$4.47 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$0.11
Average shareholder expectationRevenue Estimate
$250,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4351▲ 43.51% |
|---|---|
| Total Calls | 330,700▲ Infinity% |
| Total Puts | 143,900▲ 250.98% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 87.45%▲ 5.65% |
|---|---|
| Total Invested | $347.76M▲ 7.77% |
| Investors Holding | 202▲ 18.00% |
ESG Score
No data
About Rocket Pharmaceuticals Inc
151 employees
CEO: Gaurav Shah